1-氨基-2-甲基异硫代脲 | 44387-06-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-氨基-2-甲基异硫代脲
• 英文名称: methyl hydrazinecarbimidothioate
• 英文别名: S-Methyl-isothiosemicarbazid；methyl N'-aminocarbamimidothioate
• CAS: 44387-06-6
• 化学式: C₂H₇N₃S
• mdl: MFCD00031411
• 分子量: 105.164
• InChiKey: WQUPOMUBXOPGSN-UHFFFAOYSA-N

物化性质

• 熔点：
  136-137 °C
• 沸点：
  166.2±23.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  89.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-氨基-2-甲基异硫代脲 在 盐酸羟胺 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以70%的产率得到1-氨基-3-羟基胍
  参考文献：
  名称：

  N-Hydroxy-N′-aminoguanidines as anti-cancer lead molecule: QSAR, synthesis and biological evaluation

  摘要：

  The intrinsic pharmacophore model (r(pred)(2) and r(m)(2) of 0.858 and 0.725) has been developed and used as a query to screen in-house built library based on N-hydroxy-N'-aminoguanidine (HAG) analogs. The pharmacophoric modeled based HITs were synthesized and evaluated for anticancer activity and cytotoxicity. One of the compounds (15) appeared as promising lead candidate with an IC50 value of 11 mu M yielded in HL-60 promyelocytic leukemia cells. Compound 15 reveals significantly lower cytotoxicity against HeLa and Vero cell with CC50 values of more than 100 mu M. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.009
• 作为产物：
  描述：

  氨基硫脲 、 碘甲烷 在 乙醇 作用下， 反应 3.0h， 以96%的产率得到1-氨基-2-甲基异硫代脲
  参考文献：
  名称：

  多取代的2,3-二氢呋喃[2,3- b ]吡啶和3,4-二氢-2 H-吡喃并[2,3- b ]吡啶通过微波活化的逆电子需量Diels–Alder反应

  摘要：

  多聚2,3-二氢呋喃[2,3- b ]吡啶和3,4-二氢-2 H-吡喃并[2,3- b ]吡啶是由1,2,4-三嗪使用逆电子狄尔斯合成的。 der木反应。为此，使3-甲基硫烷基-1,2,4-三嗪与几种亲核试剂反应，使形成适当取代的炔烃进行分子内电子逆需求Diels-Alder反应。事实证明，环加成反应的密封管微波活化非常有效，并且反应时间更短。该策略使得能够有效合成3-羟基-2,3-二氢呋喃[2,3- b ]吡啶和4-羟基-3,4-二氢-2 H-吡喃并[2,3- b双环支架上具有多个多样性点的]吡啶。

  DOI：

  10.1016/j.tet.2007.05.112

文献信息

• Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
  申请人：Doyle Kevin James

  公开号：US20090318429A1

  公开（公告）日：2009-12-24

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-14 or encompassed by formulas I-XII) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物患病的组合物和方法，该疾病对通过向需要的哺乳动物投予本文所定义的化合物的有效量（包括表1-14中列出的那些化合物或被I-XII公式所包含的化合物）或其组合物来抑制功能性囊性纤维化跨膜传导调节蛋白（CFTR）多肽作出反应，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊性肾病的方法。
• [EN] 1,2,4-TRIAZINE-4-AMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZINE-4-AMINE
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2011095625A1

  公开（公告）日：2011-08-11

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.

  根据该发明提供了一种A1式化合物，可能对通过抑制A1-A2b或特别是A2a受体而得到改善的疾病或紊乱治疗有用，其中A1式化合物具有以下结构，其中，A代表Cy1或HetA；Cy1代表一个由一个、两个或三个环组成的5-至14-成员芳香、完全饱和或部分不饱和的碳环系统，该Cy1基团可选择地被一个或多个R4a取代基所取代；HetA代表一个由一个、两个或三个环组成的5-至14-成员杂环基团，可能是芳香、完全饱和或部分不饱和的，并且含有从O、S和N中选择的一个或多个杂原子，该杂环基团可能包括一个、两个或三个环，且该HetA基团可选择地被一个或多个R4b取代基所取代；B代表Cy2或HetB；Cy2代表一个由一个或两个环组成的3-至10-成员芳香、完全饱和或部分不饱和的碳环系统，该Cy2基团可选择地被一个或多个R4c取代基所取代；HetB代表一个由一个或两个环组成的3-至10-成员杂环基团，可能是芳香、完全饱和或部分不饱和的，并且含有从O、S和N中选择的一个或多个杂原子，该杂环基团可能包括一个或两个环，且该HetB基团可选择地被一个或多个R4d取代基所取代。
• New heteroaromatic aminations on 5-aryl-1,2,4-triazines and 1,2,4,5-tetrazines by palladium catalysis
  作者：Laurent Pellegatti、Emeline Vedrenne、Jean-Michel Leger、Christian Jarry、Sylvain Routier

  DOI：10.1016/j.tet.2010.03.099

  日期：2010.6

  efficient and original palladium-catalyzed amination of 5-Aryl-1,2,4-triazines and 1,2,4,5-tetrazines is reported. This Buchwald–Hartwig type reaction leads to the formation of aminated heterocycles via methylsulfur release. The reaction is optimized and a wide range of amines is used to determine the scope and limitations of this methodology.

  报道了5-芳基1,2,4-三嗪和1,2,4,5-四嗪的有效且原始的钯催化胺化。这种Buchwald-Hartwig型反应通过释放甲基硫导致胺化杂环的形成。优化了反应，并使用多种胺来确定该方法的范围和局限性。
• Sequential Michael Addition and Enamine-Promoted Inverse Electron Demanding Diels–Alder Reaction upon 3-Vinyl-1,2,4-triazine Platforms
  作者：Magali Lorion、Gérald Guillaumet、Jean-François Brière、Franck Suzenet

  DOI：10.1021/acs.orglett.5b01487

  日期：2015.6.19

  An original one-pot Michael addition-ihDA/rDA sequence was achieved from 3-vinyl-1,2,4-triazine platforms used as unprecedented Michael acceptors. This sequence provides a novel access to functionalized [2,3]-fused pyridine derivatives via a unique enamine promoted intramolecular ihDA reaction of 1,2,4-triazine intermediates.

  最初的一锅迈克尔加成反应-ih DA / r DA序列是从用作前所未见的迈克尔受体的3-乙烯基-1,2,4-三嗪平台获得的。此序列提供通过独特的烯胺的新颖存取官能[2,3] -融合吡啶衍生物促进分子内IH的1,2,4-三嗪中间体DA反应。
• Rapid synthesis of triazine inhibitors of inosine monophosphate dehydrogenase
  作者：William J. Pitts、Junqing Guo、T.G.Murali Dhar、Zhongqi Shen、Henry H. Gu、Scott H. Watterson、Mark S. Bednarz、Bang-Chi Chen、Joel C. Barrish、Donna Bassolino、Daniel Cheney、Catherine A. Fleener、Katherine A. Rouleau、Diane L. Hollenbaugh、Edwin J. Iwanowicz

  DOI：10.1016/s0960-894x(02)00351-7

  日期：2002.8

  A series of novel triazine-based small molecule inhibitors (IV) of inosine monophosphate dehydrogenase was prepared. The synthesis and the structure-activity relationships (SAR) derived from in vitro studies are described.

  制备了一系列新型的肌苷单磷酸脱氢酶的基于三嗪的小分子抑制剂（IV）。描述了合成和结构-活性关系（SAR）源自体外研究。